Verdinexor

Verdinexor (KPT-335) is an orally active inhibitor for selective inhibitor of nuclear export (SINE) . Verdinexor inhibits the respiratory syncytial virus A2 (RSV A2) replication with an IC50 of 0.96 µM. Verdinexor inhibits the function of nuclear export protein Exportin 1 (XPO1/CRM1), inhibiting pro-inflammatory responses. Verdinexor exhibits antitumor effciency[1][2].

Product Specifications

CAS Number

[1392136-43-4]

Product Name Alternative

KPT-335

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; CRM1; RSV

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/verdinexor.html

Concentration

10mM

Purity

99.94

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(NNC1=NC=CC=C1)/C=C\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2

Molecular Formula

C18H12F6N6O

Molecular Weight

442.32

Precautions

H302, H315, H319, H335

References & Citations

[1]London CA, et al., Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS One. 2014 Feb 4;9 (2) :e87585.|[2]Jorquera PA, et al., Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro. J Virol. 2019 Feb 5;93 (4) :e01684-18.